Akari Therapeutics Plc (AKTX) Q1 2025 Earnings Report

Akari Therapeutics remains in its clinical-stage phase with no revenue recognized in QQ1 2025. The quarter ended 2025-03-31 showed a net loss of $3.705 million, driven by substantial operating expenses of $3.525 million (R&D $0.813 million; G&A $2.712 million). EBITDA was negative at $3.65 million and net cash used in operating activities was $2.15 million. The company ended the quarter with roughly $2.58 million in cash and cash equivalents and a net cash outflow from operating activities that was largely offset by financing proceeds of about $2.13 million, leaving a marginal net cash decrease of $0.017 million for the period.

Balance sheet highlights reveal a high base of intangible assets ($39.18 million) and goodwill ($8.43 million), with total assets of $50.96 million and total liabilities of $29.21 million. Working capital remains tight (current ratio 0.16; quick ratio 0.16; cash ratio 0.123), underscoring a fragile near-term liquidity position that will likely necessitate additional funding or partnerships to advance the nomacopan program.

Management commentary is not provided in the supplied transcript data, limiting the ability to quote direct guidance or strategic framing. Nevertheless, the narrative for Akari hinges on the continued advancement of nomacopan across autoimmune and inflammatory indications, potential partnerships, and the need for external financing to sustain operations and late-stage development milestones. The year-over-year improvement in operating profitability metrics suggests some cost-control or spend-shaping in QQ1 2025, but the company remains loss-making with ongoing cash burn, indicating a high-risk, high-reward profile for investors focused on clinical-stage biotechnology.